Vertex Pharmaceuticals Incorporated will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss its performance for the quarter. Investors and analysts can access the live webcast through the "Investors" section of Vertex's website at www.vrtx.com .

To participate via phone, U.S. callers should dial (833) 630-2124, while international callers can reach the conference at +1 (412) 317-0651. Participants must reference the "Vertex Pharmaceuticals Second Quarter 2026 Earnings Call" when joining. The company recommends registering at least 15 minutes prior to the scheduled start time to ensure a timely connection. An archived version of the webcast will be available on the company's website following the event.

Conference Call Details

Vertex is a global biotechnology company focused on creating transformative medicines for serious diseases. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Its clinical pipeline includes investigational therapies for conditions such as IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, and type 1 diabetes. Founded in 1989, Vertex has its global headquarters in Boston and international headquarters in London.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals Inc. for $85 per share in cash, representing a total equity value of approximately $10 billion, or $8.8 billion net of cash acquired. The transaction, unanimously approved by the boards of both companies, adds Crinetics' commercialized and Phase 3 endocrinology assets to Vertex's portfolio. Vertex expects the acquisition to close in the third quarter of 2026, subject to regulatory approvals and Crinetics shareholder approval.

Strategic Rationale and Assets

The acquisition centers on two key assets. PALSONIFY (paltusotine) is the first and only once-daily oral therapy for adults with acromegaly, a rare condition affecting an estimated 20,000 diagnosed people in the U.S. Approved by the U.S. Food and Drug Administration in September 2025 and recently by the European Medicines Agency, the drug has demonstrated strong early uptake since launch. Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist, is currently in Phase 3 development for congenital adrenal hyperplasia (CAH). Classic CAH has 17,000 addressable patients in the U.S. In Phase 2 studies, patients taking atumelnant achieved near normalization of excess androgen levels on physiologic replacement doses of glucocorticoids.

Financial Impact

Vertex expects the transaction to contribute immediately to revenue growth through the ongoing launch of PALSONIFY. The company projects that at peak, these assets could deliver more than $5 billion in combined annual revenue, supporting a goal of sustained double-digit revenue growth and industry-leading operating margins. The deal is expected to become accretive to adjusted operating income in 2029.

Transaction Terms

Vertex plans to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America, N.A. and Morgan Stanley Senior Funding, Inc. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion.

Transaction Overview

Leadership and Analyst Commentary

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, described Crinetics as an excellent strategic fit due to its focus on serious diseases with significant unmet need. William Blair noted that this is the first time the firm has heard of a multi-billion dollar sales potential for a CAH product. Analyst Myles Minter stated that while the deal is on the higher side regarding stock price premium, it is viewed as reasonable if the peak sales number can be achieved. The firm believes significantly more of the >$5 billion peak sales potential is weighted toward the atumelnant opportunity, which carries more risk given its late-clinical-stage nature.